Cita APA (7a ed.)

Ikeda, T., Ogawa, S., Kitazono, T., Nakagawara, J., Minematsu, K., Miyamoto, S., . . . Hayasaki, T. (2021). Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS. Public Library of Science (PLoS).

Cita Chicago Style (17a ed.)

Ikeda, Takanori, et al. Real-world Safety and Effectiveness of Rivaroxaban Using Japan-specific Dosage During Long-term Follow-up in Patients with Atrial Fibrillation: XAPASS. Public Library of Science (PLoS), 2021.

Cita MLA (8a ed.)

Ikeda, Takanori, et al. Real-world Safety and Effectiveness of Rivaroxaban Using Japan-specific Dosage During Long-term Follow-up in Patients with Atrial Fibrillation: XAPASS. Public Library of Science (PLoS), 2021.

Precaución: Estas citas no son 100% exactas.